3.23

2.22% 0.07

After Hours: 3.20 -0.03 -0.93%

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $3.23, with a volume of 3.50M. It is up +2.22% in the last 24 hours and up +14.95% over the past month. Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Previous Close:

$3.16

Open:

$3.24

24h Volume:

3.50M

Relative Volume:

1.42

Market Cap:

$583.39M

Revenue:

$4.63M

Net Income/Loss:

$-201.14M

P/E Ratio:

-2.3506

EPS:

-1.3741

Net Cash Flow:

$-167.10M

1W Performance:

+14.54%

1M Performance:

+14.95%

6M Performance:

-10.28%

1Y Performance:

+79.44%

1-Day Range:

$3.10

$3.37

1-Week Range:

$2.76

$3.37

52-Week Range:

$1.77

$6.94

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

146

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

PRME's Discussions on Twitter

Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRME Prime Medicine Inc	3.23	583.39M	4.63M	-201.14M	-167.10M	-1.3741
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Initiated	Oppenheimer	Outperform
May-27-25	Downgrade	Citigroup	Buy → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
May-20-24	Initiated	H.C. Wainwright	Buy
May-16-24	Upgrade	Citigroup	Neutral → Buy
Apr-22-24	Initiated	Chardan Capital Markets	Buy
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform
Jan-16-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Initiated	Citigroup	Neutral
Oct-09-23	Initiated	BMO Capital Markets	Outperform
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

Jun 19, 2026

Prime Medicine’s PM-577a cleared for clinic for Wilson’s disease - BioWorld News

Jun 19, 2026

Prime Medicine receives clearance for first in vivo gene therapy trial - Investing.com Canada

Jun 19, 2026

Jun 18, 2026

Prime Medicine clears first in vivo gene-editing trial for Wilson disease - Stock Titan

Jun 18, 2026